Le Lézard
Classified in: Health, Science and technology, Business
Subject: LIC

LISCure Biosciences Announces Know-How License Agreement and Stock Purchase Agreement with Mayo Clinic

SEOUL, South Korea, Aug. 1, 2021 /PRNewswire/ -- LISCure Biosciences, Inc. ("LISCure") has entered into a know-how license and development collaboration agreement, and stock purchase agreement with Mayo Clinic to advance LISCure's microbiome therapeutics in non-alcoholic steatohepatitis (NASH).

The two entities previously entered a research collaboration agreement in the first half of 2021 for NASH candidates.

Under the agreement, the company will receive Mayo Clinic's know-how to establish a new drug development of NASH program. As part of the agreement, Mayo Clinic will become a shareholder in LISCure, the first Korean biotech company receiving equity investment from Mayo Clinic.

The two entities will pursue the common goal of maximizing the value of LISCure's therapeutics in metabolic diseases by expanding research and development activities such as discovering new indications and additional value-added candidates. LISCure plans to minimize trial and error in preparation for phase 2 clinical trial of its NASH candidate in the US in 2022 by jointly cooperating with Mayo Clinic.

"This collaboration will provide innovative treatment opportunities to patients with high medical needs in various metabolic diseases. We are very excited to establish a collaboration with Mayo Clinic," said a company official. "We are also proud of Mayo Clinic becoming our shareholder and look forward to continuing a long-term collaboration."

LISCure plans to enter the global clinical trial for NASH candidate as well as auto-immune disease candidate in the second half of this year, and to initiate clinical trial in the US for the world's first novel microbe-mediated cancer therapeutics in the first half of 2022. 

About LISCure Biosciences

LISCure was established in 2018 for the purpose of research and development of single microbial-based immunotherapy. The main focused areas are immuno-oncology, neurological diseases, autoimmune diseases, and metabolic diseases. It develops new drugs to treat patients as either monotherapy or combination therapy for major indications.

SOURCE LISCure Biosciences Inc.

These press releases may also interest you

at 18:00
Gatik today announced a new investment of $85 million in Series B funding to significantly expand North America's first autonomous Middle Mile logistics network. The round was heavily oversubscribed and brings the total amount raised by Gatik to...

at 18:00
KetamineOne Capital Limited ("Ketamine One" or the "Company") (NEO: MEDI) , a company focused on consolidating medical clinics and becoming a North American leader in mental health treatments, is pleased to announce that has retained Integral Wealth...

at 18:00
TAL Education Group ("TAL" or the "Company") , a leading K-12 after-school tutoring services provider in China, today announced that the board of directors of the Company has appointed Dr. Alex Zhuangzhuang Peng, currently the Vice President of...

at 17:58
Hardly Strictly Bluegrass continues to support the music community during the Covid-19 pandemic with a new philanthropic effort aimed at immediate relief needs and more equitable recovery. Today, the world-renowned roots music festival reveals plans...

at 17:45
Trutankless, Inc. manufactures an award-winning line of smart electric tankless water heaters. Trutankless today announced that its Board of Directors has approved a 1-for-8 reverse split (the "Reverse Stock Split") of its issued and outstanding...

at 17:41
DICK'S Sporting Goods today announced that its DICK'S House of Sport store in Knoxville has been named a Proud Corporate Partner of University of Tennessee Athletics in a first-of-its-kind partnership.   ...

News published on 1 august 2021 at 23:11 and distributed by: